M6PR as a Therapeutic Gateway
The mannose 6-phosphate receptor (M6PR) is a ubiquitously expressed endocytic receptor that mediates cellular internalization and lysosomal transport. Leveraging this endogenous pathway enables controlled intracellular routing of engineered therapeutic constructs. AMFA-Therapeutics Chimeras are designed to harness the natural M6PR-mediated lysosomal trafficking pathway. This approach expands the functional reach of antibody-based modalities by facilitating access to intracellular and lysosome-associated targets.
AMFA‑Therapeutics are constructs composed of an AMFA ligand that engages M6PR, linked to a therapeutic payload such as an antibody, enzyme, nanoparticle or biologic.
By binding M6PR at the cell surface, AMFA‑Therapeutics leverage the receptor’s native endocytic cycle to shuttle their attached therapeutic cargo into endosomes and onward to lysosomes.
This engineered pathway enables efficient cellular uptake, enhanced lysosomal delivery, and targeted degradation or activation of disease‑relevant molecules within the intracellular and lysosomal compartments.
By binding M6PR at the cell surface, AMFA‑Therapeutics leverage the receptor’s native endocytic cycle to shuttle their attached therapeutic cargo into endosomes and onward to lysosomes.
This engineered pathway enables efficient cellular uptake, enhanced lysosomal delivery, and targeted degradation or activation of disease‑relevant molecules within the intracellular and lysosomal compartments.
Platform Characteristics
- Reproducible conjugation chemistry
- Compatible with multiple biologic formats
- Optimized for scalable manufacturing
- Designed for regulatory pathway clarity
